198 related articles for article (PubMed ID: 16648296)
21. Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment.
Niziolek PJ; Murthy S; Ellis SN; Sukhija KB; Hornberger TA; Turner CH; Robling AG
J Cell Physiol; 2009 Dec; 221(3):579-85. PubMed ID: 19639601
[TBL] [Abstract][Full Text] [Related]
22. An Unanticipated Role for Sphingosine Kinase-2 in Bone and in the Anabolic Effect of Parathyroid Hormone.
Walker JM; Yao GQ; Siu E; Zhu M; Sun BH; Simpson C; Insogna KL
Endocrinology; 2021 May; 162(5):. PubMed ID: 33640975
[TBL] [Abstract][Full Text] [Related]
23. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.
Lecka-Czernik B; Ackert-Bicknell C; Adamo ML; Marmolejos V; Churchill GA; Shockley KR; Reid IR; Grey A; Rosen CJ
Endocrinology; 2007 Feb; 148(2):903-11. PubMed ID: 17122083
[TBL] [Abstract][Full Text] [Related]
24. Anabolic effect of parathyroid hormone is not modified by supplementation with insulinlike growth factor I (IGF-I) or growth hormone in aged female rats fed an energy-restricted or ad libitum diet.
Gunness M; Hock JM
Bone; 1995 Feb; 16(2):199-207. PubMed ID: 7756048
[TBL] [Abstract][Full Text] [Related]
25. Short-term systemic insulin-like growth factor-1 is unable to prevent cyclosporin A-induced osteopenia in the rat.
Mann GN; Sass DA; Chen HK; Buchinsky FJ; Bryer HP; Ma YF; Jee WS; Rucinski B; Epstein S
Calcif Tissue Int; 1996 Jul; 59(1):38-44. PubMed ID: 8661983
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis.
Boonen S; Mohan S; Dequeker J; Aerssens J; Vanderschueren D; Verbeke G; Broos P; Bouillon R; Baylink DJ
J Bone Miner Res; 1999 Dec; 14(12):2150-8. PubMed ID: 10620075
[TBL] [Abstract][Full Text] [Related]
27. Inhibited anabolic effect of insulin-like growth factor-I on stromal bone marrow cells in endothelial nitric oxide synthase-knockout mice.
Lagumdzija A; Ou G; Petersson M; Bucht E; Gonon A; Pernow Y
Acta Physiol Scand; 2004 Sep; 182(1):29-35. PubMed ID: 15329054
[TBL] [Abstract][Full Text] [Related]
28. Parathyroid hormone potentiates the effect of insulin-like growth factor-I on bone formation.
Spencer EM; Si EC; Liu CC; Howard GA
Acta Endocrinol (Copenh); 1989 Sep; 121(3):435-42. PubMed ID: 2800920
[TBL] [Abstract][Full Text] [Related]
29. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.
Locklin RM; Khosla S; Turner RT; Riggs BL
J Cell Biochem; 2003 May; 89(1):180-90. PubMed ID: 12682918
[TBL] [Abstract][Full Text] [Related]
30. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
[TBL] [Abstract][Full Text] [Related]
31. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.
Nakatani T; Chen T; Johnson J; Westendorf JJ; Partridge NC
J Bone Miner Res; 2018 Jul; 33(7):1362-1375. PubMed ID: 29544022
[TBL] [Abstract][Full Text] [Related]
32. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
[TBL] [Abstract][Full Text] [Related]
33. Amphiregulin lacks an essential role for the bone anabolic action of parathyroid hormone.
Jay FF; Vaidya M; Porada SM; Andrukhova O; Schneider MR; Erben RG
Mol Cell Endocrinol; 2015 Dec; 417():158-65. PubMed ID: 26427650
[TBL] [Abstract][Full Text] [Related]
34. Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact.
Elis S; Courtland HW; Wu Y; Fritton JC; Sun H; Rosen CJ; Yakar S
J Bone Miner Res; 2010 Sep; 25(9):2051-8. PubMed ID: 20499370
[TBL] [Abstract][Full Text] [Related]
35. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice.
Miyakoshi N; Kasukawa Y; Linkhart TA; Baylink DJ; Mohan S
Endocrinology; 2001 Oct; 142(10):4349-56. PubMed ID: 11564695
[TBL] [Abstract][Full Text] [Related]
36. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
Pettway GJ; Schneider A; Koh AJ; Widjaja E; Morris MD; Meganck JA; Goldstein SA; McCauley LK
Bone; 2005 Jun; 36(6):959-70. PubMed ID: 15878317
[TBL] [Abstract][Full Text] [Related]
37. Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism.
Novince CM; Michalski MN; Koh AJ; Sinder BP; Entezami P; Eber MR; Pettway GJ; Rosol TJ; Wronski TJ; Kozloff KM; McCauley LK
J Bone Miner Res; 2012 Jan; 27(1):11-25. PubMed ID: 21932346
[TBL] [Abstract][Full Text] [Related]
38. Ablation of Hepatic Production of the Acid-Labile Subunit in Bovine-GH Transgenic Mice: Effects on Organ and Skeletal Growth.
Liu Z; Han T; Fishman S; Butler J; Zimmermann T; Tremblay F; Harbison C; Agrawal N; Kopchick JJ; Schaffler MB; Yakar S
Endocrinology; 2017 Aug; 158(8):2556-2571. PubMed ID: 28475811
[TBL] [Abstract][Full Text] [Related]
39. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
[TBL] [Abstract][Full Text] [Related]
40. Adult-Onset Deletion of β-Catenin in (10kb)Dmp1-Expressing Cells Prevents Intermittent PTH-Induced Bone Gain.
Kedlaya R; Kang KS; Hong JM; Bettagere V; Lim KE; Horan D; Divieti-Pajevic P; Robling AG
Endocrinology; 2016 Aug; 157(8):3047-57. PubMed ID: 27253995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
